Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System.
Cardenas LM, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, Graham J, Heng D, Bjarnason G, Soulières D, Bossé D, Castonguay V, Saleh R, Tanguay S, Bhindi B, Breau RH, Pouliot F, Lalani AA. Cardenas LM, et al. Among authors: castonguay v. JCO Glob Oncol. 2023 Sep;9:e2300271. doi: 10.1200/GO.23.00271. JCO Glob Oncol. 2023. PMID: 37992270 Free PMC article.
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.
Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, Patenaude F, Breau RH, Pouliot F, Kapoor A, Wood LA. Thana M, et al. Among authors: castonguay v. Clin Genitourin Cancer. 2022 Jun;20(3):210-218. doi: 10.1016/j.clgc.2021.12.003. Epub 2021 Dec 10. Clin Genitourin Cancer. 2022. PMID: 35115252
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.
Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Kollmannsberger C, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Graham J, Bjarnason GA, Breau RH, Pouliot F, Swaminath A. Nguyen EK, et al. Among authors: castonguay v. Adv Radiat Oncol. 2022 Jan 16;7(4):100899. doi: 10.1016/j.adro.2022.100899. eCollection 2022 Jul-Aug. Adv Radiat Oncol. 2022. PMID: 35814860 Free PMC article.
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).
Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH. Lavallée LT, et al. Among authors: castonguay v. J Cancer Educ. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7. J Cancer Educ. 2019. PMID: 28779441
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. Choueiri TK, et al. Among authors: castonguay v. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. J Immunother Cancer. 2022. PMID: 36328377 Free PMC article. Clinical Trial.
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.
Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E. Lacombe L, et al. Among authors: castonguay v. Cancer Lett. 2023 Jan 28;553:215994. doi: 10.1016/j.canlet.2022.215994. Epub 2022 Nov 4. Cancer Lett. 2023. PMID: 36343786
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE. Monteith BE, et al. Among authors: castonguay v. Eur J Haematol. 2021 Sep;107(3):333-342. doi: 10.1111/ejh.13671. Epub 2021 Jun 23. Eur J Haematol. 2021. PMID: 34053112 Clinical Trial.
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ. Sahebjam S, et al. Among authors: castonguay v. Br J Cancer. 2013 Aug 20;109(4):943-9. doi: 10.1038/bjc.2013.380. Epub 2013 Jul 18. Br J Cancer. 2013. PMID: 23868004 Free PMC article. Clinical Trial.
41 results